Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent–programmed CAR T cells
Science Advances · 08.05.2026 · 12 (19)
DOI: 10.1126/sciadv.adz4088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 08.05.2026. Verfasst von Yelei Guo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bio-therapeutic, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Antigens, Neoplasm, Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Noncommunicable Chronic Diseases National Science and Technology Major Project.
Abstract (Originalsprache)
Antigen heterogeneity substantially limits the efficacy of chimeric antigen receptor–modified T (CAR T) cell therapy against solid tumors. Our study highlights the potent antitumor activity of low-dose decitabine-primed CAR T (dCAR T) cells in solid tumor models, a benefit previously confirmed in hematologic malignancies. Notably, dCAR T cell infusion in immunocompetent mice led to substantial elimination of mixed tumor masses containing both antigen-positive and antigen-negative cells, without the need for prior lymphodepletion. Our analysis showed notable proinflammatory remodeling of the tumor immunosuppressive microenvironment. Crucially, antigen-activated dCAR T cells sustained high levels of interferon-γ production, which induced immunogenic cell death in tumor cells and activated conventional dendritic cells. This, in turn, stimulated endogenous CD8 + T cells, enhancing their antigen-spreading capacity and aiding in the clearance of abscopal antigen-negative tumors. These findings reveal the robust antigen-spreading capability of dCAR T cells, underscoring their clinical potential in addressing solid tumors with inherent antigen heterogeneity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Bio-therapeutic, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
- Changping Laboratory, Beijing 102206, China.
ORCID-Profile: Yelei Guo, Chuan Tong, Jianshu Wei, Zhiqiang Wu, Yuting Lu, Yipeng Zhang, Jinhong Shi, Yao Wang, Weidong Han
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Noncommunicable Chronic Diseases National Science and Technology Major Project
Zitieren
APA
Guo, Y., Tong, C., Wei, J., Wu, Z., Lu, Y., Han, F., Zhang, Y., Wang, C., Shi, J., Shi, F., Wang, Y., & Han, W. (2026). Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent–programmed CAR T cells. Science Advances, 12(19). https://doi.org/10.1126/sciadv.adz4088
Vancouver
Guo Y, Tong C, Wei J, Wu Z, Lu Y, Han F, et al. Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent–programmed CAR T cells. Science Advances. 2026;12(19). doi:10.1126/sciadv.adz4088
BibTeX
@article{Guo2026,
author = {Guo, Yelei and Tong, Chuan and Wei, Jianshu and Wu, Zhiqiang and Lu, Yuting and Han, Fuxin and Zhang, Yipeng and Wang, Chunmeng and Shi, Jinhong and Shi, Fengxia and Wang, Yao and Han, Weidong},
title = {Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent–programmed CAR T cells},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {19},
doi = {10.1126/sciadv.adz4088}
}
EUVIMED